13 completed. 13 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 13 |
| Phase 2 | 2 | Completed 2 |
Follow Sinemet: new trials by email Literature Review of Sinemet trials Research Report on Sinemet
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg - Parkinsonian Signs in Older Persons | Phase 1 / Phase 2 | Completed | University of Michigan | 5 | 2024-10-29 | 2026-04-14 |
| Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg, Placebo 1 - Parkinsonian Signs in Older Persons | Phase 1 / Phase 2 | Completed | University of Michigan | 13 | 2024-03-15 | 2025-06-17 |
| Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis carbidopa-levodopa, Placebo Oral Tablet - Amyotrophic Lateral Sclerosis, Motor Neuron Disease | Phase 1 | Completed | Washington University School of Medicine | 15 | 2019-05-13 | 2022-07-11 |
| Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) CVT-301, Sinemet - Parkinson's Disease | Phase 1 | Completed | Acorda Therapeutics | 23 | 2019-03-05 | 2019-08-02 |
| PF 06412562 in Subjects With Advanced Stage Parkinson's Disease PF-06412562, Standard of Care Placebo - Parkinson Disease | Phase 1 | Completed | Milton S. Hershey Medical Center | 8 | 2018-09-24 | 2019-07-31 |
| A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa. Opicapone, Carbidopa Levodopa - Parkinson Disease | Phase 1 | Completed | Neurocrine Biosciences | 16 | 2018-02-08 | 2019-03-22 |
| Pharmacokinetic of Levodopa Study in Healthy Males Levodopa, carbidopa, ODM-104 - Parkinson Disease | Phase 1 | Completed | Orion Corporation, Orion Pharma | 20 | 2017-04-19 | 2017-09-26 |
| Dose-finding Pharmacokinetic Study in Healthy Males Levodopa, Carbidopa, ODM-104 - Healthy Volunteers | Phase 1 | Completed | Orion Corporation, Orion Pharma | 56 | 2017-02-21 | 2021-05-27 |
| Pharmacokinetic Study in Healthy Volunteers levodopa, carbidopa, ODM-104, levodopa, carbidopa, entacapone - Parkinson's Disease | Phase 1 | Completed | Orion Corporation, Orion Pharma | 15 | 2015-08-01 | 2016-01-14 |
| A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) Levodopa/Carbidopa (Sinemet) - Parkinson's Disease | Phase 1 | Completed | NeuroDerm Ltd. | 6 | 2015-04-01 | 2015-07-01 |
| Pharmacokinetic Study in Healthy Males levodopa, carbidopa, ODM-104 - Parkinson's Disease | Phase 1 | Completed | Orion Corporation, Orion Pharma | 20 | 2014-11-01 | 2015-02-18 |
| Levodopa Concentration Profile With Stalevo 75/125 mg Stalevo (levodopa/ carbidopa/ entacapone), Sinemet (levodopa/carbidopa) - Parkinson's Disease | Phase 1 | Completed | Orion Corporation, Orion Pharma | 20 | 2009-12-01 | 2010-08-13 |
| Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome Levodopa/Carbidopa (4:1) - Angelman Syndrome | Phase 1 | Completed | Boston Children's Hospital | 16 | 2009-01-01 | 2016-11-21 |
Parkinson Disease (8) · Amyotrophic Lateral Sclerosis (1) · Angelman Syndrome (1) · Motor Neuron Disease (1)
Orion Corporation, Orion Pharma (5) · University of Michigan (2) · Acorda Therapeutics (1) · Boston Children's Hospital (1) · Milton S. Hershey Medical Center (1) · NeuroDerm Ltd. (1) · Neurocrine Biosciences (1) · Washington University School of Medicine (1)
United States (7) · Finland (4) · Germany (1)
Chatkaew Pongmala, PhD (2) · Mika Scheinin, MD (2) · Charles Oh, MD (1) · Denis Strugala, DR.med. (1) · Kimmo Ingman (1) · Philip Evans, MBChB, MRCS (1) · Timothy M Miller, MD, PhD (1) · Wen-Hann Tan, BMBS (1) · Xuemei Huang, MD, PhD (1)
PMID 32482490, PMID 32986682, PMID 34032202
U01AG061393 (2)